- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT01064648
Pemetrexed-dinátrium és ciszplatin cediranib-maleáttal vagy anélkül a rosszindulatú pleurális mesotheliomában szenvedő betegek kezelésében
Fázis I./Véletlenszerű II. fázisú vizsgálat a cediranibről (NSC#732208) a placebóval szemben ciszplatinnal és pemetrexeddel kombinálva rosszindulatú pleurális mesotheliomában szenvedő, kemonatív betegeknél
This randomized phase I/II trial is studying the side effects and best dose of cediranib maleate when given together with pemetrexed disodium and cisplatin and to see how well it works in treating patients with malignant pleural mesothelioma. Drugs used in chemotherapy, pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving pemetrexed disodium and cisplatin together with cediranib maleate may kill more tumor cells.
A tanulmány áttekintése
Állapot
Körülmények
Részletes leírás
PRIMARY OBJECTIVES:
I. To establish the maximum tolerated dose (MTD) and the recommended phase II dose of cediranib maleate (cediranib) in combination with cisplatin and pemetrexed disodium (pemetrexed). (Phase I) II. To assess the safety and toxicity of the regimen. (Phase I) III. To assess whether cisplatin/pemetrexed plus cediranib as compared to cisplatin/pemetrexed plus placebo improves progression-free survival in patients with malignant pleural mesothelioma. (Phase II) IV. To compare overall survival in patients treated with cisplatin/pemetrexed plus cediranib to those treated with cisplatin/pemetrexed plus placebo. (Phase II) V. To assess the safety and toxicity profile of the regimen. (Phase II) VI. To assess response rate (confirmed and unconfirmed, complete and partial responses) and disease control rate (response or stable disease) in the subset of patients with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria. (Phase II) VII. To assess response rate and disease control rate using modified RECIST criteria for pleural tumors in the subset of patients with measurable disease by modified RECIST criteria for pleural tumors. (Phase II) VIII. To assess the rate of agreement between local and central pathology review of mesothelioma and its histologic subtypes. (Phase II) IX. To collect specimens for banking for use in future research studies. (Phase II)
OUTLINE: This is a phase I dose-escalation study of cediranib maleate followed by a phase II study.
PHASE I (CLOSED): Patients receive pemetrexed disodium intravenously (IV) over 10 minutes and cisplatin IV over 2 hours on day 1 and cediranib maleate orally (PO) once daily (QD) on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cediranib maleate alone PO QD in the absence of disease progression or unacceptable toxicity.
PHASE II: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cediranib maleate alone PO QD in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive pemetrexed disodium and cisplatin as in arm I and placebo PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive placebo alone PO QD in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months for 2 years and then at 3 years.
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- 2. fázis
- 1. fázis
Kapcsolatok és helyek
Tanulmányi helyek
-
-
Arkansas
-
Rogers, Arkansas, Egyesült Államok, 72758
- Highlands Oncology Group - Rogers
-
-
California
-
Antioch, California, Egyesült Államok, 94531
- Kaiser Permanente-Deer Valley Medical Center
-
Burbank, California, Egyesült Államok, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Fremont, California, Egyesült Államok, 94538
- Kaiser Permanente-Fremont
-
Fresno, California, Egyesült Államok, 93720
- Kaiser Permanente-Fresno
-
Los Angeles, California, Egyesült Államok, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Egyesült Államok, 90033
- Los Angeles General Medical Center
-
Modesto, California, Egyesült Államok, 95356
- Kaiser Permanente-Modesto
-
Oakland, California, Egyesült Államok, 94611
- Kaiser Permanente-Oakland
-
Orange, California, Egyesült Államok, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Redwood City, California, Egyesült Államok, 94063
- Kaiser Permanente-Redwood City
-
Richmond, California, Egyesült Államok, 94801
- Kaiser Permanente-Richmond
-
Roseville, California, Egyesült Államok, 95661
- Kaiser Permanente-Roseville
-
Sacramento, California, Egyesült Államok, 95817
- University of California Davis Comprehensive Cancer Center
-
Sacramento, California, Egyesült Államok, 95823
- Kaiser Permanente-South Sacramento
-
Sacramento, California, Egyesült Államok, 95825
- Kaiser Permanente Sacramento Medical Center
-
San Francisco, California, Egyesült Államok, 94115
- Kaiser Permanente-San Francisco
-
San Jose, California, Egyesült Államok, 95119
- Kaiser Permanente-Santa Teresa-San Jose
-
San Leandro, California, Egyesült Államok, 94577
- Kaiser Permanente San Leandro
-
San Rafael, California, Egyesült Államok, 94903
- Kaiser Permanente-San Rafael
-
Santa Clara, California, Egyesült Államok, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Rosa, California, Egyesült Államok, 95403
- Kaiser Permanente-Santa Rosa
-
South San Francisco, California, Egyesült Államok, 94080
- Kaiser Permanente-South San Francisco
-
Stockton, California, Egyesült Államok, 95210
- Kaiser Permanente-Stockton
-
Vacaville, California, Egyesült Államok, 95688
- Kaiser Permanente Medical Center-Vacaville
-
Vallejo, California, Egyesült Államok, 94589
- Kaiser Permanente-Vallejo
-
Walnut Creek, California, Egyesült Államok, 94596
- Kaiser Permanente-Walnut Creek
-
-
Connecticut
-
Hartford, Connecticut, Egyesült Államok, 06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
-
Florida
-
Orlando, Florida, Egyesült Államok, 32806
- Orlando Health Cancer Institute
-
-
Georgia
-
Gainesville, Georgia, Egyesült Államok, 30501
- Northeast Georgia Medical Center-Gainesville
-
-
Hawaii
-
Honolulu, Hawaii, Egyesült Államok, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Egyesült Államok, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Egyesült Államok, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Egyesült Államok, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, Egyesült Államok, 96817
- Hawaii Cancer Care Inc-Liliha
-
Honolulu, Hawaii, Egyesült Államok, 96817
- Kuakini Medical Center
-
Honolulu, Hawaii, Egyesült Államok, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, Egyesült Államok, 96826
- Kapiolani Medical Center for Women and Children
-
Honolulu, Hawaii, Egyesült Államok, 96819
- Kaiser Permanente Moanalua Medical Center
-
Kailua, Hawaii, Egyesült Államok, 96734
- Castle Medical Center
-
Lihue, Hawaii, Egyesült Államok, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea, Hawaii, Egyesült Államok, 96701
- Pali Momi Medical Center
-
‘Aiea, Hawaii, Egyesült Államok, 96701
- Queen's Cancer Center - Pearlridge
-
-
Idaho
-
Boise, Idaho, Egyesült Államok, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Coeur d'Alene, Idaho, Egyesült Államok, 83814
- Kootenai Health - Coeur d'Alene
-
Post Falls, Idaho, Egyesült Államok, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Egyesült Államok, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
-
Illinois
-
Bloomington, Illinois, Egyesült Államok, 61704
- Illinois CancerCare-Bloomington
-
Bloomington, Illinois, Egyesült Államok, 61701
- OSF Saint Joseph Medical Center
-
Canton, Illinois, Egyesült Államok, 61520
- Illinois CancerCare-Canton
-
Carbondale, Illinois, Egyesült Államok, 62902
- Memorial Hospital of Carbondale
-
Carthage, Illinois, Egyesült Államok, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Egyesült Államok, 62801
- Centralia Oncology Clinic
-
Decatur, Illinois, Egyesült Államok, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Egyesült Államok, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Decatur, Illinois, Egyesült Államok, 62526
- Heartland Cancer Research NCORP
-
Effingham, Illinois, Egyesült Államok, 62401
- Crossroads Cancer Center
-
Eureka, Illinois, Egyesült Államok, 61530
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Egyesült Államok, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Egyesült Államok, 61401
- Illinois CancerCare-Galesburg
-
Kewanee, Illinois, Egyesült Államok, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Egyesült Államok, 61455
- Illinois CancerCare-Macomb
-
O'Fallon, Illinois, Egyesült Államok, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Egyesült Államok, 61350
- Illinois CancerCare-Ottawa Clinic
-
Ottawa, Illinois, Egyesült Államok, 61350
- Radiation Oncology of Northern Illinois
-
Pekin, Illinois, Egyesült Államok, 61554
- Illinois CancerCare-Pekin
-
Pekin, Illinois, Egyesült Államok, 61554
- OSF Saint Francis Radiation Oncology at Pekin
-
Peoria, Illinois, Egyesült Államok, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Egyesült Államok, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, Egyesült Államok, 61615
- Illinois CancerCare-Peoria
-
Peoria, Illinois, Egyesült Államok, 61615
- OSF Saint Francis Radiation Oncology at Peoria Cancer Center
-
Peru, Illinois, Egyesült Államok, 61354
- Illinois CancerCare-Peru
-
Peru, Illinois, Egyesült Államok, 61354
- Valley Radiation Oncology
-
Princeton, Illinois, Egyesült Államok, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Egyesült Államok, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Egyesült Államok, 62702
- Springfield Clinic
-
Springfield, Illinois, Egyesült Államok, 62702
- Central Illinois Hematology Oncology Center
-
Springfield, Illinois, Egyesült Államok, 62781
- Springfield Memorial Hospital
-
-
Indiana
-
Beech Grove, Indiana, Egyesült Államok, 46107
- Franciscan Saint Francis Health-Beech Grove
-
Indianapolis, Indiana, Egyesült Államok, 46237
- Franciscan Health Indianapolis
-
Richmond, Indiana, Egyesült Államok, 47374
- Reid Health
-
-
Kansas
-
Topeka, Kansas, Egyesült Államok, 66606
- Cotton O'Neil Cancer Center / Stormont Vail Health
-
-
Kentucky
-
Crestview Hills, Kentucky, Egyesült Államok, 41017
- Oncology Hematology Care Inc-Crestview
-
Lexington, Kentucky, Egyesült Államok, 40536
- University of Kentucky/Markey Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, Egyesült Államok, 48106
- Michigan Cancer Research Consortium NCORP
-
Ann Arbor, Michigan, Egyesült Államok, 48109
- University of Michigan Rogel Cancer Center
-
Ann Arbor, Michigan, Egyesült Államok, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Dearborn, Michigan, Egyesült Államok, 48124
- Corewell Health Dearborn Hospital
-
Detroit, Michigan, Egyesült Államok, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Egyesült Államok, 48201
- Wayne State University/Karmanos Cancer Institute
-
Detroit, Michigan, Egyesült Államok, 48236
- Henry Ford Health Saint John Hospital
-
Farmington Hills, Michigan, Egyesült Államok, 48334
- Weisberg Cancer Treatment Center
-
Flint, Michigan, Egyesült Államok, 48532
- Genesys Regional Medical Center-West Flint Campus
-
Flint, Michigan, Egyesült Államok, 48503
- Hurley Medical Center
-
Flint, Michigan, Egyesült Államok, 48503
- Genesys Hurley Cancer Institute
-
Jackson, Michigan, Egyesült Államok, 49201
- Allegiance Health
-
Lansing, Michigan, Egyesült Államok, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Egyesült Államok, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Egyesült Államok, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Port Huron, Michigan, Egyesült Államok, 48060
- Lake Huron Medical Center
-
Saginaw, Michigan, Egyesült Államok, 48601
- MyMichigan Medical Center Saginaw
-
Warren, Michigan, Egyesült Államok, 48093
- Henry Ford Health Warren Hospital
-
-
Mississippi
-
Pascagoula, Mississippi, Egyesült Államok, 39581
- Singing River Hospital
-
-
Missouri
-
Bonne Terre, Missouri, Egyesült Államok, 63628
- Parkland Health Center-Bonne Terre
-
Cape Girardeau, Missouri, Egyesült Államok, 63703
- Saint Francis Medical Center
-
Cape Girardeau, Missouri, Egyesült Államok, 63703
- Mercy Cancer Center - Cape Girardeau
-
Jefferson City, Missouri, Egyesült Államok, 65109
- MU Health Care Goldschmidt Cancer Center
-
Sainte Genevieve, Missouri, Egyesült Államok, 63670
- Sainte Genevieve County Memorial Hospital
-
St Louis, Missouri, Egyesült Államok, 63131
- Missouri Baptist Medical Center
-
Sullivan, Missouri, Egyesült Államok, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Anaconda, Montana, Egyesült Államok, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Egyesült Államok, 59101
- Billings Clinic Cancer Center
-
Billings, Montana, Egyesült Államok, 59101
- Saint Vincent Healthcare
-
Billings, Montana, Egyesült Államok, 59102
- Montana Cancer Consortium NCORP
-
Billings, Montana, Egyesült Államok, 59102
- Saint Vincent Frontier Cancer Center
-
Bozeman, Montana, Egyesült Államok, 59715
- Bozeman Health Deaconess Hospital
-
Butte, Montana, Egyesült Államok, 59701
- Saint James Community Hospital and Cancer Treatment Center
-
Great Falls, Montana, Egyesült Államok, 59405
- Great Falls Clinic
-
Great Falls, Montana, Egyesült Államok, 59405
- Benefis Sletten Cancer Institute
-
Helena, Montana, Egyesült Államok, 59601
- Saint Peter's Community Hospital
-
Kalispell, Montana, Egyesült Államok, 59901
- Glacier Oncology PLLC
-
Kalispell, Montana, Egyesült Államok, 59901
- Logan Health Medical Center
-
Missoula, Montana, Egyesült Államok, 59802
- Saint Patrick Hospital - Community Hospital
-
Missoula, Montana, Egyesült Államok, 59802
- Montana Cancer Specialists
-
Missoula, Montana, Egyesült Államok, 59804
- Community Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, Egyesült Államok, 28204
- Novant Health Presbyterian Medical Center
-
Charlotte, North Carolina, Egyesült Államok, 28207
- Oncology Specialists of Charlotte
-
Charlotte, North Carolina, Egyesült Államok, 28262
- Southern Oncology Specialists-Charlotte
-
Charlotte, North Carolina, Egyesült Államok, 28207
- Novant Health Carolina Surgical - Randolph
-
Hendersonville, North Carolina, Egyesült Államok, 28791
- Margaret R Pardee Memorial Hospital
-
Huntersville, North Carolina, Egyesült Államok, 28078
- Novant Health Cancer Institute - Huntersville
-
Huntersville, North Carolina, Egyesült Államok, 28078
- Southern Oncology Specialists-Huntersville
-
Matthews, North Carolina, Egyesült Államok, 28105
- Matthews Radiation Oncology Center
-
Matthews, North Carolina, Egyesült Államok, 28105
- Novant Health Cancer Institute - Matthews
-
Mooresville, North Carolina, Egyesült Államok, 28117
- Novant Health Cancer Institute - Mooresville
-
Statesville, North Carolina, Egyesült Államok, 28677
- Iredell Memorial Hospital
-
Winston-Salem, North Carolina, Egyesült Államok, 27104
- Southeast Clinical Oncology Research Consortium NCORP
-
-
Ohio
-
Belpre, Ohio, Egyesült Államok, 45714
- Strecker Cancer Center-Belpre
-
Chillicothe, Ohio, Egyesült Államok, 45601
- Adena Regional Medical Center
-
Cincinnati, Ohio, Egyesült Államok, 45242
- Oncology Hematology Care Inc-Blue Ash
-
Cincinnati, Ohio, Egyesült Államok, 45202
- Oncology Hematology Care Inc-Eden Park
-
Cincinnati, Ohio, Egyesült Államok, 45211
- Oncology Hematology Care Inc-Mercy West
-
Cincinnati, Ohio, Egyesült Államok, 45230
- Oncology Hematology Care Inc-Anderson
-
Cincinnati, Ohio, Egyesült Államok, 45236
- Oncology Hematology Care Inc-Kenwood
-
Columbus, Ohio, Egyesült Államok, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Egyesült Államok, 43219
- The Mark H Zangmeister Center
-
Columbus, Ohio, Egyesült Államok, 43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus, Ohio, Egyesült Államok, 43228
- Doctors Hospital
-
Columbus, Ohio, Egyesült Államok, 43213
- Mount Carmel East Hospital
-
Columbus, Ohio, Egyesült Államok, 43215
- Grant Medical Center
-
Columbus, Ohio, Egyesült Államok, 43222
- Mount Carmel Health Center West
-
Columbus, Ohio, Egyesült Államok, 43215
- Columbus NCI Community Oncology Research Program
-
Dayton, Ohio, Egyesült Államok, 45406
- Good Samaritan Hospital - Dayton
-
Dayton, Ohio, Egyesült Államok, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Egyesült Államok, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Egyesült Államok, 45405
- Grandview Hospital
-
Dayton, Ohio, Egyesült Államok, 45459
- Dayton NCI Community Oncology Research Program
-
Delaware, Ohio, Egyesült Államok, 43015
- Delaware Health Center-Grady Cancer Center
-
Delaware, Ohio, Egyesült Államok, 43015
- Delaware Radiation Oncology
-
Delaware, Ohio, Egyesült Államok, 43015
- Grady Memorial Hospital
-
Fairfield, Ohio, Egyesült Államok, 45014
- Oncology Hematology Care Inc-Healthplex
-
Findlay, Ohio, Egyesült Államok, 45840
- Blanchard Valley Hospital
-
Franklin, Ohio, Egyesült Államok, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Greenville, Ohio, Egyesült Államok, 45331
- Wayne Hospital
-
Kettering, Ohio, Egyesült Államok, 45429
- Kettering Medical Center
-
Lancaster, Ohio, Egyesült Államok, 43130
- Fairfield Medical Center
-
Mansfield, Ohio, Egyesült Államok, 44903
- OhioHealth Mansfield Hospital
-
Marietta, Ohio, Egyesült Államok, 45750
- Marietta Memorial Hospital
-
Marion, Ohio, Egyesült Államok, 43302
- OhioHealth Marion General Hospital
-
Mount Vernon, Ohio, Egyesült Államok, 43050
- Knox Community Hospital
-
Newark, Ohio, Egyesült Államok, 43055
- Licking Memorial Hospital
-
Newark, Ohio, Egyesült Államok, 43055
- Newark Radiation Oncology
-
Portsmouth, Ohio, Egyesült Államok, 45662
- Southern Ohio Medical Center
-
Springfield, Ohio, Egyesült Államok, 45504
- Springfield Regional Medical Center
-
Troy, Ohio, Egyesült Államok, 45373
- Upper Valley Medical Center
-
Westerville, Ohio, Egyesült Államok, 43081
- Saint Ann's Hospital
-
Xenia, Ohio, Egyesült Államok, 45385
- Greene Memorial Hospital
-
Zanesville, Ohio, Egyesült Államok, 43701
- Genesis Healthcare System Cancer Care Center
-
-
Oregon
-
Clackamas, Oregon, Egyesült Államok, 97015
- Clackamas Radiation Oncology Center
-
Milwaukie, Oregon, Egyesült Államok, 97222
- Providence Milwaukie Hospital
-
Newberg, Oregon, Egyesült Államok, 97132
- Providence Newberg Medical Center
-
Oregon City, Oregon, Egyesült Államok, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Egyesült Államok, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Egyesült Államok, 97225
- Providence Saint Vincent Medical Center
-
-
South Carolina
-
Boiling Springs, South Carolina, Egyesült Államok, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Easley, South Carolina, Egyesült Államok, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, Egyesült Államok, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Egyesült Államok, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Egyesült Államok, 29605
- Prisma Health Cancer Institute - Butternut
-
Greenville, South Carolina, Egyesült Államok, 29605
- Prisma Health Greenville Memorial Hospital
-
Greenville, South Carolina, Egyesült Államok, 29601
- Greenville Health System Cancer Institute-Andrews
-
Greer, South Carolina, Egyesült Államok, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, Egyesült Államok, 29672
- Prisma Health Cancer Institute - Seneca
-
-
Tennessee
-
Bristol, Tennessee, Egyesült Államok, 37620
- Wellmont Medical Associates Oncology and Hematology-Bristol
-
Bristol, Tennessee, Egyesült Államok, 37620
- Bristol Regional Medical Center
-
Johnson City, Tennessee, Egyesült Államok, 37604
- Wellmont Medical Associates Oncology and Hematology-Johnson City
-
Kingsport, Tennessee, Egyesült Államok, 37660
- Ballad Health Cancer Care - Kingsport
-
Kingsport, Tennessee, Egyesült Államok, 37660
- Wellmont Holston Valley Hospital and Medical Center
-
-
Texas
-
Houston, Texas, Egyesült Államok, 77030
- UT MD Anderson Cancer Center
-
-
Virginia
-
Danville, Virginia, Egyesült Államok, 24541
- Danville Regional Medical Center
-
Norton, Virginia, Egyesült Államok, 24273
- Ballad Health Cancer Care - Norton
-
-
Washington
-
Anacortes, Washington, Egyesült Államok, 98221
- Cancer Care Center at Island Hospital
-
Bellingham, Washington, Egyesült Államok, 98225
- PeaceHealth Saint Joseph Medical Center
-
Burien, Washington, Egyesült Államok, 98166
- Saint Anne Hospital
-
Edmonds, Washington, Egyesült Államok, 98026
- Swedish Cancer Institute-Edmonds
-
Issaquah, Washington, Egyesült Államok, 98029
- Swedish Cancer Institute-Issaquah
-
Kennewick, Washington, Egyesült Államok, 99336
- Kadlec Clinic Hematology and Oncology
-
Kirkland, Washington, Egyesült Államok, 98034
- FHCC at EvergreenHealth
-
Longview, Washington, Egyesült Államok, 98632
- PeaceHealth Saint John Medical Center
-
Mount Vernon, Washington, Egyesült Államok, 98274
- Skagit Valley Hospital
-
Poulsbo, Washington, Egyesült Államok, 98370
- Harrison HealthPartners Hematology and Oncology-Poulsbo
-
Seattle, Washington, Egyesült Államok, 98104
- Harborview Medical Center
-
Seattle, Washington, Egyesült Államok, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Egyesült Államok, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Egyesült Államok, 98195
- University of Washington Medical Center - Montlake
-
Seattle, Washington, Egyesült Államok, 98112
- Kaiser Permanente Washington
-
Seattle, Washington, Egyesült Államok, 98104
- Minor and James Medical PLLC
-
Seattle, Washington, Egyesült Államok, 98109
- Fred Hutchinson Cancer Center
-
Sedro-Woolley, Washington, Egyesült Államok, 98284
- PeaceHealth United General Medical Center
-
Silverdale, Washington, Egyesült Államok, 98383
- Saint Joseph Medical Center Hematology and Oncology - Silverdale
-
Spokane, Washington, Egyesült Államok, 99218
- Evergreen Hematology and Oncology PS
-
Spokane, Washington, Egyesült Államok, 99202
- Cancer Care Northwest - Spokane South
-
Spokane, Washington, Egyesült Államok, 99220
- Rockwood Clinic
-
Vancouver, Washington, Egyesült Államok, 98664
- PeaceHealth Southwest Medical Center
-
Vancouver, Washington, Egyesült Államok, 98684
- Compass Oncology Vancouver
-
Wenatchee, Washington, Egyesült Államok, 98801
- Wenatchee Valley Hospital and Clinics
-
-
Wyoming
-
Casper, Wyoming, Egyesült Államok, 82609
- Rocky Mountain Oncology
-
Cody, Wyoming, Egyesült Államok, 82414
- Big Horn Basin Cancer Center
-
Cody, Wyoming, Egyesült Államok, 82414
- Billings Clinic-Cody
-
Sheridan, Wyoming, Egyesült Államok, 82801
- Welch Cancer Center
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Patient must have histologically or cytologically confirmed diagnosis of malignant pleural mesothelioma; surgical resection must not be planned
- Patients must have measurable or non-measurable disease by both RECIST and modified RECIST criteria for pleural tumors as documented by computed tomography (CT) scan; examinations for assessment of measurable disease must have been completed within 28 days prior to registration; examinations for assessment of non-measurable disease must have been performed within 42 days prior to registration; all disease must be assessed and documented on the RECIST 1.1 and Modified RECIST Baseline Tumor Assessment Form
- Patients must not have received any prior systemic therapy (chemotherapy or other biologic therapy) for their unresectable malignant pleural mesothelioma; prior systemic chemotherapy or biologic therapy is allowed as neoadjuvant or adjuvant treatment, disease has now recurred, and all systemic treatment was completed > 6 months prior registration; prior therapy must not have included cediranib
- Patients may have received prior surgery (e.g., pleurectomy, pleurodeisis) provided at least 28 days have elapsed since surgery (thoracic or other major surgeries) and patients have recovered from all associated toxicities at the time of registration; there must be no anticipated need for major surgical procedures during protocol treatment
- Patients may have received prior radiation therapy provided at least 28 days have elapsed since the last treatment and patients have recovered from all associated toxicities at the time of registration
- Institutions must seek additional patient consent for the banking and future use of specimens
- Patient must have Zubrod performance status 0-2
- Absolute neutrophil count >= 1,500 mcl
- Platelets >= 100,000/ml
- Hemoglobin >= 9.0 g/dl (may be reached by transfusion)
- Total bilirubin =< 1.5 x institutional upper limit of normal (IULN)
- Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) =< 2.5 x ULN (if liver metastases are present, SGOT or SGPT must be =< 5.0 x IULN)
- Serum creatinine =< 1.5 x IULN
- Calculated creatinine clearance >= 60 mL/min
- Urine protein must be screened by urine analysis within 28 days prior to registration; patient must not have greater than +1 proteinuria on two consecutive dipsticks taken no less than 7 days apart; however, if the first urinalysis shows no protein, then a repeat urinalysis is not required
- Patient must have an electrocardiogram (ECG) performed within 42 days prior to registration; patient must not have mean corrected QT (QTc) > 500 msec (with Bazett's correction) in screening electrocardiogram, or other significant ECG abnormality, New York Heart Association (NYHA) classification III or IV; patient must not require concurrent use of drugs or biologics with proarrhythmic potential
- Patient must not be receiving any medication that may markedly affect renal function (e.g., vancomycin, amphotericin, pentamidine)
- Patient must not have had clinically significant hemoptysis, defined as greater than 1 tablespoon of bright red blood, within one year prior to registration; although hemoptysis has not been associated with cediranib, it may be a class effect for anti-angiogenic agents and therefore a risk factor for this experimental agent
- Patient must be able to swallow oral medications
- Patients must not have known human immunodeficiency virus (HIV) infection
- Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
- Patient must have no plans to receive concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy or any other type of therapy for treatment of cancer while on this protocol treatment
- No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Kettős
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: Arm I (pemetrexed disodium, cisplatin, cediranib maleate))
Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cediranib maleate alone PO QD in the absence of disease progression or unacceptable toxicity. |
Correlative studies Given IV
Más nevek:
Given IV
Más nevek:
Given orally
Más nevek:
|
|
Aktív összehasonlító: Arm II (pemetrexed disodium, cisplatin, placebo)
Patients receive pemetrexed disodium and cisplatin as in arm I and placebo PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive placebo alone PO QD in the absence of disease progression or unacceptable toxicity. |
Correlative studies Given IV
Más nevek:
Given IV
Más nevek:
Given orally |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Maximum Tolerated Dose of Cediranib in Combination With Cisplatin and Pemetrexed (Phase I)
Időkeret: Weekly during first cycle (1cycle = 21 days). Then will be reported every cycle while patient is on treatment.
|
MTD was determined by testing dose-de-escalation to 20mg PO daily on dose de-escalation cohort 1 to 2 with 3 to 6 patients each. MTD reflects the highest dose of drug that did not cause a Dose-Limiting Toxicity (DLT) in > 33% of participants. Toxicities will be graded according to the CTEP Active Version of the NCI Common Terminology Criteria for Adverse Events. Dose-limiting toxicities (DLT) apply only during Cycle 1 and must be drug-related (i.e. possibly, probably or definitely related to one of the 3 study drugs). The following events occurring in the first cycle of treatment are considered dose limiting.
|
Weekly during first cycle (1cycle = 21 days). Then will be reported every cycle while patient is on treatment.
|
|
Progression-free Survival (Phase II)
Időkeret: From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, whichever came first, assessed up to 5 years.Disease assessment will be repeated every 6 weeks until disease progression.
|
From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression free are censored at date of last contact. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v 1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesions, or the appearance of new lesions. |
From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, whichever came first, assessed up to 5 years.Disease assessment will be repeated every 6 weeks until disease progression.
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Overall Survival (Phase II)
Időkeret: From date of registration to death.Disease assessment will be repeated every 6 weeks until disease progression. After progression, follow up will occur every 6 months for the first two years and then at the end of the third year after registration.
|
From date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact. |
From date of registration to death.Disease assessment will be repeated every 6 weeks until disease progression. After progression, follow up will occur every 6 months for the first two years and then at the end of the third year after registration.
|
|
Response Rate by RECIST1.1 (Phase II)
Időkeret: Disease assessment will be repeated every 6 weeks until disease progression, up to 3 years. Best response is documented for as long as the patient remains on protocol treatment.
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1): Complete Response (CR), Disappearance of all measurable and non-measurable disease; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. All target measurable lesions must be assessed using the same techniques as baseline. |
Disease assessment will be repeated every 6 weeks until disease progression, up to 3 years. Best response is documented for as long as the patient remains on protocol treatment.
|
|
Disease Control Rate by RECIST 1.1 (Phase II)
Időkeret: Disease assessment will be repeated every 6 weeks until disease progression, up to 3 years.Disease control rate is documented for as long as the patient remains on protocol treatment.
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1): Complete Response (CR), Disappearance of all measurable and non-measurable disease; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (STA): Does not qualify for CR, PR, Progression or Symptomatic Deterioration. Disease Control Rate (DCR) = CR + PR + STA All target measurable lesions must be assessed using the same techniques as baseline. |
Disease assessment will be repeated every 6 weeks until disease progression, up to 3 years.Disease control rate is documented for as long as the patient remains on protocol treatment.
|
|
Response Rate by Modified RECIST (Phase II)
Időkeret: Disease assessment will be repeated every 6 weeks until disease progression, up to 3 years.Best response is documented for as long as the patient remains on protocol treatment.
|
Per modified RECIST for Pleural Tumors. In addition to RECIST1.1, for modified RECIST, measurements based on the sum of 6 CT cuts in the pleural perpendicular to the chest wall are applied to standard RECIST criterial (sum of 6 = one univariate diameter). Complete Response (CR), Disappearance of all measurable and non-measurable disease; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. All target measurable lesions must be assessed using the same techniques as baseline. |
Disease assessment will be repeated every 6 weeks until disease progression, up to 3 years.Best response is documented for as long as the patient remains on protocol treatment.
|
|
Disease Control Rate by Modified RECIST (Phase II)
Időkeret: Disease assessment will be repeated every 6 weeks until disease progression, up to 3 years.Disease control is documented for as long as the patient remains on protocol treatment.
|
Per modified RECIST for Pleural Tumors. In addition to RECIST1.1, for modified RECIST, measurements based on the sum of 6 CT cuts in the pleural perpendicular to the chest wall are applied to standard RECIST criterial (sum of 6 = one univariate diameter). Complete Response (CR), Disappearance of all measurable and non-measurable disease; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (STA), does not qualify for CR, PR, Progression or Symptomatic Deterioration. Disease Control Rate (DCR) = CR + PR + STA. All target measurable lesions must be assessed using the same techniques as baseline. |
Disease assessment will be repeated every 6 weeks until disease progression, up to 3 years.Disease control is documented for as long as the patient remains on protocol treatment.
|
|
(Phase I) Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
Időkeret: Toxicity assessment is repeated weekly during first cycle (1cycle = 21 days), then every cycle while patient is on treatment.
|
Adverse Events (AEs) are reported by CTCAE Version 4.0. Only adverse events that are possibly, probably or definitely related to study drug are reported. |
Toxicity assessment is repeated weekly during first cycle (1cycle = 21 days), then every cycle while patient is on treatment.
|
|
(Phase II) Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
Időkeret: Toxicity assessment is repeated every 3 weeks while patient is on treatment.
|
Adverse Events (AEs) are reported by CTCAE Version 4.0. Only adverse events that are possibly, probably or definitely related to study drug are reported. |
Toxicity assessment is repeated every 3 weeks while patient is on treatment.
|
Együttműködők és nyomozók
Szponzor
Nyomozók
- Kutatásvezető: Anne S Tsao, SWOG Cancer Research Network
Publikációk és hasznos linkek
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Becsült)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
- Neoplazmák webhelyenként
- Neoplazmák
- Légúti betegségek
- Neoplazmák szövettani típus szerint
- Tüdőbetegségek
- Neoplazmák, mirigyes és epiteliális
- Légúti neoplazmák
- Mellkasi neoplazmák
- Tüdő neoplazmák
- Adenoma
- Neoplazmák, mezoteliális
- Pleurális neoplazmák
- Neoplazmák, kötő- és lágyszövetek
- Neoplazmák, kötőszövet
- Neoplazmák, rostos szövetek
- Mesothelioma
- Magányos rostos daganatok
- Mesothelioma, rosszindulatú
- Solitaris rostos daganat, mellhártya
- Aminosavak, peptidek és fehérjék
- Heterociklusos vegyületek
- Heterociklusos vegyületek, 2 gyűrű
- Heterociklusos vegyületek, olvasztott gyűrű
- Szervetlen vegyi anyagok
- Klórvegyületek
- Nitrogénvegyületek
- Guanin
- Hipoxantinok
- Purinonok
- Purinák
- Glutamátok
- Aminosavak, savas
- Aminosavak
- Aminosavak, dikarboxilsav
- Elemek
- Fémek
- Fémek, nehéz
- Platinavegyületek
- Átmeneti elemek
- Pemetrexed
- Ciszplatin
- 1,2-diamino-ciklohexán-platina-II citrát
- Platina
- cediranib
Egyéb vizsgálati azonosító számok
- NCI-2011-02015
- U10CA032102 (Az Egyesült Államok NIH támogatása/szerződése)
- U10CA180888 (Az Egyesült Államok NIH támogatása/szerződése)
- U10CA180830 (Az Egyesült Államok NIH támogatása/szerződése)
- NCI-2011-02015 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- CDR0000665415
- S0905 (Egyéb azonosító: CTEP)
- S0905
- S0905 (Egyéb azonosító: SWOG)
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .